循环生物标志物预测激素敏感或去势抵抗性转移性前列腺癌患者治疗反应的系统综述
该系统综述检索了2013年3月至2024年2月Medline、Web of Science及循证网站,评估循环生物标志物对转移性前列腺癌治疗反应的预测价值。在转移性去势抵抗性前列腺癌中,BRCA1/2或ATM突变预测雄激素受体通路抑制剂(LOE IB)和PARP抑制剂(LOE IIB)反应,循环肿瘤细胞中AR-V7预测雄激素受体通路抑制剂和紫杉烷类反应(LOE IB)。作者认为BRCA1/2、ATM和AR改变可能有助于临床管理,其他标志物尚未达到常规临床使用所需证据水平。
要点
- mCRPC中BRCA1/2或ATM突变预测ARPIs反应(LOE IB)和PARPIs反应(LOE IIB)。
- mCRPC中CTC的AR-V7转录本或蛋白预测ARPIs和紫杉烷类反应(LOE IB)。
- CTC定量预测卡巴他赛、阿比特龙和镭-223反应(LOE IIB),TP53改变预测177Lu-PSMA放射配体治疗反应(LOE IIB)。
核心结论
- 液体活检检测的BRCA1/2、ATM和AR改变可能有助于临床医生管理转移性前列腺癌患者。
- 其他循环生物标志物未达到常规临床使用所需的证据水平,应在前瞻性独立研究中验证。
研究设计与样本
- 系统综述,检索Medline、Web of Science和循证网站2013年3月至2024年2月关于转移性前列腺癌循环生物标志物的出版物。
- 终点为预测总生存、生化或影像学无进展生存(治疗后:化疗、雄激素剥夺治疗、雄激素受体通路抑制剂、免疫治疗或PARP抑制剂)。
- 证据水平(LOE)分级:LOE IA和IB为高证据水平;LOE IIB和IIC为中等证据水平;LOE IIIC和LOE IV-VD为弱证据水平。
主要发现
- mCRPC中BRCA1/2或ATM突变预测ARPIs反应(LOE IB)和PARPIs反应(LOE IIB)。
- mCRPC中CTC的AR-V7转录本或AR-V7蛋白水平预测ARPIs和紫杉烷类反应(LOE IB)。
- mCRPC中CTC定量预测卡巴他赛、阿比特龙和镭-223反应(LOE IIB)。
- mCRPC中TP53改变预测177Lu前列腺特异性膜抗原放射配体治疗反应(LOE IIB)。
- mCRPC中首次治疗线前和后续线前循环肿瘤DNA的AR拷贝数预测多西他赛、卡巴他赛和ARPIs反应(LOE IIB);mHSPC中淋巴细胞DNA损伤预测镭-223反应(LOE IIB)。
关键数值与推荐
- mCRPC中BRCA1/2或ATM突变预测ARPIs反应(LOE IB)和PARPIs反应(LOE IIB)。
- mCRPC中CTC的AR-V7转录本或AR-V7蛋白水平预测ARPIs和紫杉烷类反应(LOE IB)。
- mCRPC中CTC定量预测卡巴他赛、阿比特龙和镭-223反应(LOE IIB)。
- mCRPC中TP53改变预测177Lu前列腺特异性膜抗原放射配体治疗反应(LOE IIB)。
- mCRPC中首次治疗线前和后续线前循环肿瘤DNA的AR拷贝数预测多西他赛、卡巴他赛和ARPIs反应(LOE IIB);mHSPC中淋巴细胞DNA损伤预测镭-223反应(LOE IIB)。
临床怎么用
- 作者认为,液体活检检测的BRCA1/2、ATM和AR改变可能有助于临床医生管理转移性前列腺癌患者。
- 其他循环生物标志物未达到常规临床使用所需的证据水平,作者建议应在前瞻性独立研究中验证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be identified not only in tissue but also directly in biologic fluids (ie, liquid biopsies), mainly blood. Liquid biopsies may represent a safer and less invasive alternative for monitoring patients treated for mPCa. Current research focuses on the description and validation of novel predictive biomarkers to improve precision medicine in mPCa. Our aim was to systematically review the current evidence on liquid biopsy biomarkers for predicting treatment response in mPCa. METHODS: We systematically searched Medline, Web of Science, and evidence-based websites for publications on circulating biomarkers in mPCa between March 2013 and February 2024 for review. Endpoints were: prediction of overall survival, biochemical or radiographic progression-free survival after treatment (chemotherapy, androgen deprivation therapy, androgen receptor pathway inhibitors [ARPIs], immunotherapy, or PARP inhibitors [PARPIs]). For each biomarker, the level of evidence (LOE) for clinical validity was attributed: LOE IA and IB, high level of evidence; LOE IIB and IIC, intermediate level; and LOE IIIC and LOE IV-VD, weak level. KEY FINDINGS AND LIMITATIONS: The predictive value of each biomarker for the response to several therapies was evaluated in both metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). In patients with mCRPC, BRCA1/2 or ATM mutations predicted response to ARPIs (LOE IB) and PARPIs (LOE IIB), while AR-V7 transcripts or AR-V7 protein levels in circulating tumor cells (CTCs) predicted response to ARPIs and taxanes (LOE IB). CTC quantification predicted response to cabazitaxel, abiraterone, and radium-223 (LOE IIB), while TP53 alterations predicted response to 177Lu prostate-specific membrane antigen radioligand treatment (LOE IIB). AR copy number in circulating tumor DNA before the first treatment line and before subsequent lines predicted response to docetaxel, cabazitaxel, and ARPIs (LOE IIB). In mHSPC, DNA damage in lymphocytes was predictive of the response to radium-223 (LOE IIB). CONCLUSIONS AND CLINICAL IMPLICATIONS: BRCA1/2, ATM, and AR alterations detected in liquid biopsies may help clinicians in management of patients with mPCa. The other circulating biomarkers did not reach the LOE required for routine clinical use and should be validated in prospective independent studies. PATIENT SUMMARY: We reviewed studies assessing the value of biomarkers in blood or urine for management of metastatic prostate cancer. The evidence indicates that some biomarkers could help in selecting patients eligible for specific treatments.
引用
- Baboudjian M, Peyrottes A, Dariane C, et al. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review. Eur Urol Oncol. 2024. PMID: 38824003. doi:10.1016/j.euo.2024.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。